What to expect on retatrutide is an important question for anyone considering or currently enrolled in a clinical trial involving this investigational medicine. Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, placing it in a distinct class from existing weight-management treatments such as semaglutide and tirzepatide. As of mid-2025, it remains unlicensed by the MHRA and EMA, with Phase 3 trials ongoing. This article outlines what participants can expect regarding dosing, side effects, appetite and weight changes, safety considerations, and the monitoring involved in trial settings.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors; it remains unlicensed by the MHRA and EMA as of mid-2025 and is only available within approved clinical trials.

Retatrutide is an investigational injectable medicine currently under clinical development for the treatment of obesity and type 2 diabetes. Unlike earlier weight-management medicines, retatrutide is a triple receptor agonist, meaning it simultaneously targets three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-action mechanism distinguishes it from dual agonists such as tirzepatide and single agonists such as semaglutide.

Based on current evidence, GLP-1 receptor activation is thought to slow gastric emptying, reduce appetite, and improve insulin secretion in a glucose-dependent manner. The GIP component may further enhance insulin release and support fat metabolism. Glucagon receptor activity is hypothesised to increase energy expenditure and promote fat breakdown (lipolysis), which researchers believe may contribute to the substantial weight loss observed in early trials — though these mechanisms continue to be investigated.

It is important to note that, as of mid-2025, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). Phase 3 trials (the TRIUMPH programme) are ongoing. Retatrutide is not available as a licensed treatment through the NHS, and any use outside of an approved clinical trial would be considered unlicensed. Always seek guidance from a qualified healthcare professional before considering any investigational medicine.

Starting Retatrutide: Dosing and the Titration Schedule

Retatrutide is given as a once-weekly subcutaneous injection, starting at 2 mg in Phase 2 protocols and escalating to 8–12 mg; all dosing is governed by the clinical-trial protocol and must not be self-adjusted.

Based on data from Phase 2 clinical trials published in the New England Journal of Medicine (2023), retatrutide is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. The medicine follows a structured dose-escalation (titration) schedule designed to minimise gastrointestinal side effects whilst allowing the body to gradually adapt.

In the Phase 2 trial protocol, participants began at a low starting dose — commonly 2 mg once weekly — before progressing through incremental increases over several months, with target maintenance doses ranging from 8 mg to 12 mg weekly depending on tolerability and clinical response. These figures are provided as examples from a specific research protocol only; they do not represent a licensed prescribing schedule.

Important points about dosing:

• All dosing decisions — including starting dose, titration steps, and how to manage a missed dose — are determined by the clinical-trial protocol and the supervising investigators. There is no standard clinical dosing schedule because the medicine is unlicensed.

• Do not adjust your dose without instruction from your trial team.

• Injections should be administered on the same day each week.

• Training on injection technique and sharps disposal will be provided by the trial site.

Patients should never source or self-administer investigational medicines outside of approved research settings. If you have questions about your dosing schedule, contact your trial team directly.

Common Side Effects and How to Manage Them

Gastrointestinal effects — including nausea, vomiting, and diarrhoea — are the most common side effects, typically peaking during dose escalation and improving with smaller meals, adequate hydration, and avoidance of high-fat foods.

As with other GLP-1-based therapies, the most frequently reported side effects of retatrutide are gastrointestinal in nature. These are most common during the dose-escalation phase and tend to improve as the body adjusts to the medicine.

Common side effects include:

• Nausea and vomiting

• Diarrhoea or constipation

• Abdominal discomfort or bloating

• Reduced appetite (which, whilst an intended effect, can occasionally be excessive)

• Belching or indigestion

Most of these effects are mild to moderate in severity and transient. Practical strategies to manage them include eating smaller, more frequent meals; avoiding high-fat or heavily spiced foods; staying well hydrated; and eating slowly. Nausea is typically worst in the first few days following a dose increase.

Less commonly, participants in trials reported injection site reactions such as redness, bruising, or mild swelling. These are generally self-limiting. Fatigue, dizziness, and headache have also been reported, particularly during the early weeks of treatment.

As a class effect shared with GLP-1 receptor agonists, gallbladder problems — including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) — have been observed with this type of medicine, and may be more likely with rapid weight loss. Seek urgent medical assessment if you develop pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice).

A modest increase in resting heart rate has been observed with GLP-1-based medicines. If you notice persistent palpitations or a sustained increase in resting heart rate, discuss this with your supervising clinician.

Contact your supervising clinician promptly if you experience:

• Persistent or severe vomiting that prevents adequate fluid intake

• Signs of dehydration (dark urine, dizziness, confusion)

• Severe abdominal pain, particularly radiating to the back (which may indicate pancreatitis)

• Upper right abdominal pain, fever, or jaundice (which may indicate a gallbladder problem)

The glucagon receptor activity of retatrutide means that blood glucose monitoring is particularly important for individuals with diabetes who are also taking insulin or sulphonylureas, as these combinations may increase the risk of hypoglycaemia (low blood sugar). If you are on either of these medicines, discuss potential dose adjustments with your trial team before starting retatrutide. Be aware of the signs of hypoglycaemia — including shakiness, sweating, confusion, and palpitations — and know how to treat it promptly.

If you suspect you have experienced a side effect, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

What Changes to Expect in Weight, Appetite and Energy

Appetite suppression is usually one of the earliest effects, often noticeable within one to two weeks; weight loss is gradual and progressive, with results varying according to diet, activity, and individual factors.

One of the most notable findings from Phase 2 trials is the magnitude of weight loss associated with retatrutide. In the 2023 New England Journal of Medicine Phase 2 obesity trial, participants receiving the highest doses (12 mg weekly) achieved an average body weight reduction of approximately 24% over 48 weeks, alongside structured lifestyle support. These results have generated considerable interest within the obesity medicine community.

Direct comparisons with other licensed agents should be made cautiously, as trials differ in their populations, designs, and lifestyle support components. Long-term maintenance of weight loss and outcomes following discontinuation of retatrutide have not yet been established.

In terms of day-to-day experience, appetite suppression is typically one of the earliest noticeable effects, often beginning within the first one to two weeks. Many people report feeling full more quickly, having less interest in food between meals, and experiencing fewer cravings — particularly for high-calorie or ultra-processed foods. This is largely attributable to GLP-1 and GIP receptor activity slowing gastric emptying and modulating hunger signals in the brain.

Changes in energy levels can be variable. Some individuals report improved energy and motivation as weight decreases and metabolic health improves. However, during the initial weeks — particularly around dose increases — mild fatigue is not uncommon and may be related to reduced caloric intake or the body adapting to altered metabolism.

It is important to maintain realistic expectations:

• Weight loss is typically gradual and progressive, not immediate

• Results vary between individuals based on diet, physical activity, genetics, and adherence

• Sustainable lifestyle changes — including a balanced diet and regular physical activity — remain essential alongside any pharmacological treatment

• Weight may plateau before the maintenance dose is reached; this is normal

Important Safety Considerations and Who Should Avoid It

Retatrutide requires particular caution in people with a history of medullary thyroid carcinoma, MEN2, acute pancreatitis, severe gastrointestinal disorders, or pregnancy, and should only be accessed through registered, ethics-approved clinical trials.

Whilst retatrutide has demonstrated a broadly acceptable safety profile in trials to date, there are important considerations that would likely inform prescribing decisions if and when it receives regulatory approval.

Retatrutide may require particular caution or may not be suitable for individuals with:

• A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — based on findings in rodent studies, this is a precaution shared across the GLP-1 receptor agonist class in EU and UK product information. The relevance to humans is not established, but if you notice a neck lump, difficulty swallowing, persistent hoarseness, or unexplained neck pain, inform your clinician promptly.

• A history of acute pancreatitis or significant pancreatic disease

• Severe gastrointestinal disorders, such as gastroparesis

• Pregnancy or breastfeeding — weight-loss medicines are not appropriate during pregnancy. Women of childbearing potential should use effective contraception during treatment and discuss preconception planning and any required washout period with their trial team or clinician before attempting to conceive.

• Significant hepatic or renal impairment — data in these populations are currently limited. Suitability will be guided by trial inclusion and exclusion criteria until a formal product licence and prescribing information are available.

The glucagon receptor agonism in retatrutide introduces additional considerations not seen with GLP-1-only agents. Glucagon stimulates hepatic glucose production, which may affect glycaemic control in people with diabetes. Close monitoring is therefore warranted in this population.

There is currently no guidance from NICE or the MHRA regarding retatrutide, as it remains unlicensed. Patients should be cautious about unregulated sources offering access to investigational medicines, as these carry significant safety risks including unknown purity, incorrect dosing, and absence of medical oversight. The MHRA has issued warnings about falsified weight-loss injections available online.

Anyone considering participation in a clinical trial involving retatrutide should ensure the trial is registered on a recognised database (such as ClinicalTrials.gov or the ISRCTN registry) and has been approved by a UK Research Ethics Committee.

Monitoring and Follow-Up During Retatrutide Treatment

Trial participants undergo structured monitoring of weight, blood glucose, HbA1c, lipids, liver and renal function, blood pressure, and heart rate, typically every four weeks during dose escalation.

Within clinical trial settings, participants receiving retatrutide undergo structured and regular monitoring to ensure both safety and efficacy. The specific monitoring schedule and tests required are defined by the clinical-trial protocol; outside of an approved trial there is no standard monitoring framework, as the medicine is unlicensed.

Monitoring parameters typically assessed in trials include:

• Body weight and BMI — measured at each visit to track progress

• Blood glucose and HbA1c — particularly important for participants with type 2 diabetes or non-diabetic hyperglycaemia (sometimes called prediabetes)

• Lipid profile — including total cholesterol, LDL, HDL, and triglycerides

• Liver function tests — given the metabolic effects of glucagon receptor activation

• Renal function — especially relevant if gastrointestinal side effects lead to reduced fluid intake

• Blood pressure and heart rate — cardiovascular parameters are routinely assessed

• Calcitonin levels — some trial protocols include calcitonin measurement given the theoretical thyroid C-cell risk associated with GLP-1 receptor agonists, based on rodent data. Routine thyroid function testing is not a standard class recommendation in UK or EU prescribing information for GLP-1 receptor agonists; however, patients should be aware of thyroid-related symptoms (neck lump, hoarseness, difficulty swallowing) and report them promptly.

Follow-up appointments are typically scheduled every four weeks during the titration phase, and less frequently once a stable maintenance dose is established. Participants are encouraged to keep a symptom diary and report any new or worsening symptoms between visits.

From a patient safety perspective, it is essential to inform all treating clinicians — including your GP — that you are receiving retatrutide, as it may interact with other medicines or influence the management of co-existing conditions. If you experience any sudden or severe symptoms at any point during treatment, seek urgent medical attention and do not wait for your next scheduled appointment.

If you believe you have experienced a side effect, report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. As the evidence base for retatrutide continues to grow, future NICE guidance and MHRA decisions will shape how this medicine may be integrated into NHS care pathways for obesity and metabolic disease.

Frequently Asked Questions